Review
Recent key advances in human immunodeficiency virus medicine and implications for China
-
* Corresponding authors: Myron S Cohen mscohen@med.unc.edu - Fujie Zhang treatment@chinaaids.cn
1 School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
2 Washington University in St. Louis, St. Louis, MO, USA
3 Division of Treatment and Care, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 27 Nanwei Road, Beijing 100050, PR China
4 National Institute of Allergy and Infectious Diseases, National Institutes of Health, based at the U.S. Embassy Beijing, No. 55 An Jia Lou Lu, Beijing 100600, PR China
5 China Medical University, Shengyang, Liaoning, PR China
AIDS Research and Therapy 2010, 7:12 doi:10.1186/1742-6405-7-12
Published: 26 May 2010Abstract
In this article we summarize several recent major developments in human immunodeficiency virus treatment, prevention, outcome, and social policy change. Updated international guidelines endorse more aggressive treatment strategies and safer antiretroviral drugs. New antiretroviral options are being tested. Important lessons were learned in the areas of human immunodeficiency virus vaccines and microbicide gels from clinical studies, and additional trials in prevention, especially pre-exposure prophylaxis, are nearing completion. Insight into the role of the virus in the pathogenesis of diseases traditionally thought to be unrelated to acquired immunodeficiency syndrome has become a driving force for earlier and universal therapy. Lastly, we review important achievements of and future challenges facing China as she steps into her eighth year of the National Free Antiretroviral Treatment Program.